We are live on ! Find out more
NRXP icon

NRX Pharmaceuticals

32 hedge funds and large institutions have $4.78M invested in NRX Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,226% more capital inflows, than outflows

Capital inflows: $4.24M | Capital outflows: $182K

1,133% more call options, than puts

Call options by funds: $74K | Put options by funds: $6K

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

9.67% more ownership

Funds ownership: 4.4% → 14.07% (+9.7%)

7% more funds holding

Funds holding: 30 → 32 (+2)

Holders
32
Holders Change
+2
Holders Change %
+6.67%
% of All Funds
0.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
6
Reduced
5
Closed
4
Calls
$74​K
Puts
$6​K
Net Calls
+$68​K
Net Calls Change
-⁠$28​K

NRXP Hedge Fund Activity: Q2 2023 in Review

32 of the 6,391 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q2 2023, worth a combined $4.78M — up 131% from $2.07M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new NRXP positions and 4 closed out — a net gain of 2 holders — while 6 added to existing stakes and 5 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $3.39M. The largest seller was BlackRock, cutting an estimated $50.8K.

  • 32 institutional investors held NRX Pharmaceuticals (NRXP) as of Q2 2023, up from 30 in Q1 2023.
  • Funds reported $4.78M of NRX Pharmaceuticals stock for Q2 2023, up 131% quarter-over-quarter.
  • 6 funds opened new NRX Pharmaceuticals positions in Q2 2023 and 4 closed out, a net change of +2 holders.
  • The largest NRX Pharmaceuticals buyer in Q2 2023 was Armistice Capital, an estimated $3.39M added.
  • The largest NRX Pharmaceuticals seller in Q2 2023 was BlackRock, an estimated $50.8K sold.

Based on aggregated 13F filings for Q2 2023.